These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 22647602)

  • 1. Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration.
    Dehay B; Ramirez A; Martinez-Vicente M; Perier C; Canron MH; Doudnikoff E; Vital A; Vila M; Klein C; Bezard E
    Proc Natl Acad Sci U S A; 2012 Jun; 109(24):9611-6. PubMed ID: 22647602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lysosomal dysfunction in Parkinson disease: ATP13A2 gets into the groove.
    Dehay B; Martinez-Vicente M; Ramirez A; Perier C; Klein C; Vila M; Bezard E
    Autophagy; 2012 Sep; 8(9):1389-91. PubMed ID: 22885599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PARK9-associated ATP13A2 localizes to intracellular acidic vesicles and regulates cation homeostasis and neuronal integrity.
    Ramonet D; Podhajska A; Stafa K; Sonnay S; Trancikova A; Tsika E; Pletnikova O; Troncoso JC; Glauser L; Moore DJ
    Hum Mol Genet; 2012 Apr; 21(8):1725-43. PubMed ID: 22186024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lysosomal impairment in Parkinson's disease.
    Dehay B; Martinez-Vicente M; Caldwell GA; Caldwell KA; Yue Z; Cookson MR; Klein C; Vila M; Bezard E
    Mov Disord; 2013 Jun; 28(6):725-32. PubMed ID: 23580333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutated ATP10B increases Parkinson's disease risk by compromising lysosomal glucosylceramide export.
    Martin S; Smolders S; Van den Haute C; Heeman B; van Veen S; Crosiers D; Beletchi I; Verstraeten A; Gossye H; Gelders G; Pals P; Hamouda NN; Engelborghs S; Martin JJ; Eggermont J; De Deyn PP; Cras P; Baekelandt V; Vangheluwe P; Van Broeckhoven C;
    Acta Neuropathol; 2020 Jun; 139(6):1001-1024. PubMed ID: 32172343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ATP13A2-mediated endo-lysosomal polyamine export counters mitochondrial oxidative stress.
    Vrijsen S; Besora-Casals L; van Veen S; Zielich J; Van den Haute C; Hamouda NN; Fischer C; Ghesquière B; Tournev I; Agostinis P; Baekelandt V; Eggermont J; Lambie E; Martin S; Vangheluwe P
    Proc Natl Acad Sci U S A; 2020 Dec; 117(49):31198-31207. PubMed ID: 33229544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parkinson's disease-associated ATP13A2/PARK9 functions as a lysosomal H
    Fujii T; Nagamori S; Wiriyasermkul P; Zheng S; Yago A; Shimizu T; Tabuchi Y; Okumura T; Fujii T; Takeshima H; Sakai H
    Nat Commun; 2023 Apr; 14(1):2174. PubMed ID: 37080960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parkinson's disease-linked human PARK9/ATP13A2 maintains zinc homeostasis and promotes α-Synuclein externalization via exosomes.
    Kong SM; Chan BK; Park JS; Hill KJ; Aitken JB; Cottle L; Farghaian H; Cole AR; Lay PA; Sue CM; Cooper AA
    Hum Mol Genet; 2014 Jun; 23(11):2816-33. PubMed ID: 24603074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of ATP13A2 via PHD2-HIF1α Signaling Is Critical for Cellular Iron Homeostasis: Implications for Parkinson's Disease.
    Rajagopalan S; Rane A; Chinta SJ; Andersen JK
    J Neurosci; 2016 Jan; 36(4):1086-95. PubMed ID: 26818499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deficiency of ATP13A2 leads to lysosomal dysfunction, α-synuclein accumulation, and neurotoxicity.
    Usenovic M; Tresse E; Mazzulli JR; Taylor JP; Krainc D
    J Neurosci; 2012 Mar; 32(12):4240-6. PubMed ID: 22442086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lysosomal Storage of Subunit c of Mitochondrial ATP Synthase in Brain-Specific Atp13a2-Deficient Mice.
    Sato S; Koike M; Funayama M; Ezaki J; Fukuda T; Ueno T; Uchiyama Y; Hattori N
    Am J Pathol; 2016 Dec; 186(12):3074-3082. PubMed ID: 27770614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuropathology in an α-synuclein preformed fibril mouse model occurs independent of the Parkinson's disease-linked lysosomal ATP13A2 protein.
    Massari CM; Dues DJ; Bergsma A; Sipple K; Frye M; Williams ET; Moore DJ
    Neurobiol Dis; 2024 Nov; 202():106701. PubMed ID: 39406291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hereditary Parkinsonism-Associated Genetic Variations in PARK9 Locus Lead to Functional Impairment of ATPase Type 13A2.
    Park JS; Sue CM
    Curr Protein Pept Sci; 2017; 18(7):725-732. PubMed ID: 26965689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogenic LRRK2 mutations, through increased kinase activity, produce enlarged lysosomes with reduced degradative capacity and increase ATP13A2 expression.
    Henry AG; Aghamohammadzadeh S; Samaroo H; Chen Y; Mou K; Needle E; Hirst WD
    Hum Mol Genet; 2015 Nov; 24(21):6013-28. PubMed ID: 26251043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ATP13A2 deficiency induces a decrease in cathepsin D activity, fingerprint-like inclusion body formation, and selective degeneration of dopaminergic neurons.
    Matsui H; Sato F; Sato S; Koike M; Taruno Y; Saiki S; Funayama M; Ito H; Taniguchi Y; Uemura N; Toyoda A; Sakaki Y; Takeda S; Uchiyama Y; Hattori N; Takahashi R
    FEBS Lett; 2013 May; 587(9):1316-25. PubMed ID: 23499937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ATP13A2/PARK9 regulates endo-/lysosomal cargo sorting and proteostasis through a novel PI(3, 5)P2-mediated scaffolding function.
    Demirsoy S; Martin S; Motamedi S; van Veen S; Holemans T; Van den Haute C; Jordanova A; Baekelandt V; Vangheluwe P; Agostinis P
    Hum Mol Genet; 2017 May; 26(9):1656-1669. PubMed ID: 28334751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased Lysosomal Exocytosis Induced by Lysosomal Ca
    Tsunemi T; Perez-Rosello T; Ishiguro Y; Yoroisaka A; Jeon S; Hamada K; Rammonhan M; Wong YC; Xie Z; Akamatsu W; Mazzulli JR; Surmeier DJ; Hattori N; Krainc D
    J Neurosci; 2019 Jul; 39(29):5760-5772. PubMed ID: 31097622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nigral ATP13A2 depletion induces Parkinson's disease-related neurodegeneration in a pilot study in non-human primates.
    Sikora J; Dovero S; Kinet R; Arotcarena ML; Bohic S; Bezard E; Fernagut PO; Dehay B
    NPJ Parkinsons Dis; 2024 Aug; 10(1):141. PubMed ID: 39090150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutations in the ATP13A2 gene and Parkinsonism: a preliminary review.
    Yang X; Xu Y
    Biomed Res Int; 2014; 2014():371256. PubMed ID: 25197640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. α-Synuclein-induced dopaminergic neurodegeneration in a rat model of Parkinson's disease occurs independent of ATP13A2 (PARK9).
    Daniel G; Musso A; Tsika E; Fiser A; Glauser L; Pletnikova O; Schneider BL; Moore DJ
    Neurobiol Dis; 2015 Jan; 73():229-43. PubMed ID: 25461191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.